Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits

Abayomi B Ogundele, Guangming Li, Joel J EllisAlcon Research, Ltd., Fort Worth, TX, USAIntroduction: The purpose of this study was to examine and compare the conjunctival irritation (congestion, swelling, and discharge) of topical bimatoprost ophthalmic solution 0.01% and bimatoprost ophthalmic solu...

Full description

Bibliographic Details
Main Authors:	Abayomi B Ogundele, Guangming Li, Joel J Ellis
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-02-01
Series:	Clinical Ophthalmology
Online Access:	http://www.dovepress.com/impact-of-topical-bimatoprost-001-and-bimatoprost-003-on-conjunctival--a3970

Similar Items

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
by: Chang-Lin J-E, et al.
Published: (2011-08-01)

The Effect of Topical Bimatoprost 0.03% Solution on Androgenic Alopecia
by: Dwi Aryaningrum, et al.
Published: (2018-11-01)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
by: Abayomi B Ogundele, et al.
Published: (2010-06-01)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study
by: Deshpande SS, et al.
Published: (2017-07-01)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
by: Shafiee A, et al.
Published: (2013-07-01)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
by: Myers JS, et al.
Published: (2014-03-01)

Floppy eyelid syndrome and ectropion improvement after 1 month of 0.03% Bimatoprost topical therapy
by: Alessandra De Gregorio, et al.
Published: (2020-12-01)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
by: Moataz E Gheith, et al.
Published: (2008-03-01)

The efficiency of monotherapy of patients with primary open-angle glaucoma with Bimatoprost 0.03 % (Bimoptic)
by: S. A. Korotkikh, et al.
Published: (2018-12-01)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
by: Inoue K, et al.
Published: (2014-06-01)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
by: Umbelino Cristiano C, et al.
Published: (2008-06-01)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
by: Pfennigsdorf S, et al.
Published: (2016-09-01)

Evaluation of palpebral fissure and orbital volume after bimatoprost 0.03% orbital injections. Experimental study in rats
by: Nilson Lopes da Fonseca Junior, et al.
Published: (2014-12-01)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
by: Tsumura T, et al.
Published: (2012-09-01)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
by: Pillunat LE, et al.
Published: (2016-09-01)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
by: Tsumura T, et al.
Published: (2013-07-01)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
by: E Randy Craven, et al.
Published: (2010-12-01)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
by: Tsumura T, et al.
Published: (2013-01-01)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
by: Schnober D, et al.
Published: (2015-05-01)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
by: Campbell JH, et al.
Published: (2014-05-01)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
by: Laube T, et al.
Published: (2012-05-01)

Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360° synechial angle-closure glaucoma: A preliminary study
by: Vyas Prateep, et al.
Published: (2011-01-01)

Bimatoprost in dermatology
by: Abhijeet K Jha, et al.
Published: (2018-01-01)

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
by: Wirta D, et al.
Published: (2011-06-01)

Corneal alterations induced by topical application of commercial latanoprost, travoprost and bimatoprost in rabbit.
by: Wensheng Chen, et al.
Published: (2014-01-01)

A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension
by: Navreet Kaur Natt, et al.
Published: (2014-01-01)

An observational study of bimatoprost 0.01% in treatment-na&iuml;ve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
by: Nixon DR, et al.
Published: (2012-12-01)

Correction: Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
by: The Staff
Published: (2014-01-01)

Correction: Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit.
Published: (2014-01-01)

Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
by: Francesco Oddone, et al.
Published: (2015-01-01)

Periorbital muscle atrophy associated with topical bimatoprost therapy
by: Wang PX, et al.
Published: (2014-01-01)

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan® RC Early Analysis Review (CLEAR) trial
by: Crichton AC, et al.
Published: (2014-05-01)

Bimatoprost in the treatment of eyelash hypotrichosis
by: Simon K Law
Published: (2010-04-01)

A comparative study in treatment of childhood vitiligo 0.03% tacrolimus versus 0.03% tacrolimus and topical steroids
by: Anandan Venkatesan, et al.
Published: (2021-01-01)

A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
by: Stevens A, et al.
Published: (2016-04-01)

Intraocular Pressure and Conjunctival Hyperaemia with Bimatoprost Every 48 Hours Versus Every 24 Hours
by: Daniele Doro, et al.
Published: (2009-01-01)

Management of hypotrichosis of the eyelashes: Focus on bimatoprost
by: Steven Fagien
Published: (2010-04-01)

Tear biomarkers in latanoprost and bimatoprost treated eyes.
by: Shweta Reddy, et al.
Published: (2018-01-01)

Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis
by: Chanasumon N, et al.
Published: (2018-02-01)

Bimatoprost Effects on Aqueous Humor Dynamics in Monkeys
by: David F. Woodward, et al.
Published: (2010-01-01)

Cannot write session to /tmp/vufind_sessions/sess_aeqosh2kvtfh1b02g4hmi9u7gj